Table of Contents
Leukemia Research and Treatment
Volume 2014, Article ID 421723, 9 pages
http://dx.doi.org/10.1155/2014/421723
Research Article

Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

1Division of Clinical Research, Fred Hutchinson Cancer Research Center, P.O. Box 19024, Seattle, WA 98109, USA
2Department of Medicine, University of Washington, Seattle, WA 98195, USA
3Department of Pathology, University of Washington, Seattle, WA 98195, USA
4Department of Pediatrics, University of Washington, Seattle, WA 98195, USA
5Department of Biostatistics, University of Washington, Seattle, WA 98195, USA

Received 26 November 2013; Revised 28 January 2014; Accepted 9 February 2014; Published 23 March 2014

Academic Editor: Giuseppe Gaipa

Copyright © 2014 Merav Bar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. H. Terwey, T. M. le Duc, P. G. Hemmati et al., “NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia,” Annals of Oncology, vol. 24, no. 5, pp. 1363–1370. View at Publisher · View at Google Scholar
  2. J. Tracey, M. J. Zhang, E. Thiel, K. A. Sobocinski, and M. Eapen, “Transplantation conditioning regimens and outcomes after allogeneic hematopoietic cell transplantation in children and adolescents with acute lymphoblastic leukemia,” Biology of Blood and Marrow Transplantation, vol. 19, pp. 255–259, 2013. View at Publisher · View at Google Scholar
  3. N. Bunin, D. A. Johnston, W. M. Roberts et al., “Residual leukaemia after bone marrow transplant in children with acute lymphoblastic leukaemia after first haematological relapse or with poor initial presenting features,” British Journal of Haematology, vol. 120, no. 4, pp. 711–715, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Campana, “Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?” Current Hematologic Malignancy Reports, vol. 7, no. 2, pp. 170–177, 2012. View at Google Scholar
  5. M. Brüggemann, T. Raff, and M. Kneba, “Has MRD monitoring superseded other prognostic factors in adult ALL?” Blood, vol. 120, no. 23, pp. 4470–4481, 2012. View at Publisher · View at Google Scholar
  6. M. Schrappe, “Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient,” Hematology, vol. 2012, no. 1, pp. 137–142, 2012. View at Publisher · View at Google Scholar
  7. J. J. M. van Dongen, T. Seriu, E. R. Panzer-Grümayer et al., “Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood,” The Lancet, vol. 352, no. 9142, pp. 1731–1738, 1998. View at Google Scholar · View at Scopus
  8. C. J. C. Knechtli, N. J. Goulden, J. P. Hancock et al., “Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia,” Blood, vol. 92, no. 11, pp. 4072–4079, 1998. View at Google Scholar · View at Scopus
  9. V. H. J. van der Velden, S. A. Joosten, M. J. Willemse et al., “Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia,” Leukemia, vol. 15, no. 9, pp. 1485–1487, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Uzunel, J. Mattsson, M. Jaksch, M. Remberger, and O. Ringdén, “The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia,” Blood, vol. 98, no. 6, pp. 1982–1984, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Bader, J. Hancock, H. Kreyenberg et al., “Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL,” Leukemia, vol. 16, no. 9, pp. 1668–1672, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. O. Krejci, V. H. J. van der Velden, P. Bader et al., “Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of The Pre-BMT MRD Study Group,” Bone Marrow Transplantation, vol. 32, no. 8, pp. 849–851, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Uzunel, M. Jaksch, J. Mattsson, and O. Ringdén, “Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia,” British Journal of Haematology, vol. 122, no. 5, pp. 788–794, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Sramkova, K. Muzikova, E. Fronkova et al., “Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia,” Pediatric Blood and Cancer, vol. 48, no. 1, pp. 93–100, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Spinelli, B. Peruta, M. Tosi et al., “Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia,” Haematologica, vol. 92, no. 5, pp. 612–618, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Bader, H. Kreyenberg, G. H. R. Henze et al., “Prognostic value of Minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: The ALL-REZ BFM Study Group,” Journal of Clinical Oncology, vol. 27, no. 3, pp. 377–384, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Wood, “9-Color and 10-color flow cytometry in the clinical laboratory,” Archives of Pathology and Laboratory Medicine, vol. 130, no. 5, pp. 680–690, 2006. View at Google Scholar · View at Scopus
  18. E. Coustan-Smith, J. Sancho, M. L. Hancock et al., “Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia,” Blood, vol. 96, no. 8, pp. 2691–2696, 2000. View at Google Scholar · View at Scopus
  19. M. Bruggemann, A. Schrauder, T. Raff et al., “Standardized MRD quantification in European all trials: Poceedings of the 2nd International Symposium on MRD Assessment in Kiel, Germany, 18–20 September 2008,” Leukemia, vol. 24, no. 3, pp. 521–535, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Coustan-Smith and D. Campana, “Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing,” Best Practice and Research: Clinical Haematology, vol. 23, no. 3, pp. 347–358, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. M. N. Dworzak, G. Fröschl, D. Printz et al., “Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia,” Blood, vol. 99, no. 6, pp. 1952–1958, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Gaipa, G. Cazzaniga, M. G. Valsecchi et al., “Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia,” Haematologica, vol. 97, no. 10, pp. 1582–1593, 2012. View at Publisher · View at Google Scholar
  23. G. Kerst, H. Kreyenberg, C. Roth et al., “Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR,” British Journal of Haematology, vol. 128, no. 6, pp. 774–782, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. M.-B. Vidriales, J. J. Pérez, M. C. López-Berges et al., “Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value,” Blood, vol. 101, no. 12, pp. 4695–4700, 2003. View at Google Scholar · View at Scopus
  25. M. Malec, V. H. J. van der Velden, E. Björklund et al., “Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping,” Leukemia, vol. 18, no. 10, pp. 1630–1636, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Holowiecki, M. Krawczyk-Kulis, S. Giebel et al., “Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study,” British Journal of Haematology, vol. 142, no. 2, pp. 227–237, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Basso, M. Veltroni, M. G. Valsecchi et al., “Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow,” Journal of Clinical Oncology, vol. 27, no. 31, pp. 5168–5174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. J. Borowitz, M. Devidas, S. P. Hunger et al., “Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study,” Blood, vol. 111, no. 12, pp. 5477–5485, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Sánchez, J. Serrano, P. Gómez et al., “Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation,” British Journal of Haematology, vol. 116, no. 3, pp. 686–694, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. X.-S. Zhao, Y.-R. Liu, H.-H. Zhu et al., “Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation,” Annals of Hematology, vol. 91, no. 2, pp. 183–192, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. B. L. Wood, “Chapter 6: unit 6.21: ten-color immunophenotyping of hematopoietic cells,” in Current Protocols in Cytometry, 2005. View at Google Scholar
  32. W. Leung, C. H. Pui, E. Coustan-Smith et al., “Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia,” Blood, vol. 120, no. 2, pp. 468–472, 2012. View at Publisher · View at Google Scholar
  33. T. Miyazaki, H. Fujita, K. Fujimaki et al., “Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia,” Leukemia Research, vol. 36, no. 8, pp. 998–1003, 2012. View at Google Scholar
  34. D. L. Stirewalt, K. A. Guthrie, L. Beppu et al., “Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation,” Biology of blood and Marrow Transplantation, vol. 9, no. 3, pp. 206–212, 2003. View at Google Scholar · View at Scopus